BC Week In Review | Jul 18, 2016
Clinical News

Adapalene 0 regulatory update

Galderma said Japan approved Epiduo adapalene/benzoyl peroxide to treat acne vulgaris. Galderma expects partner Maruho to launch the once-daily gel formulation of 0.1% adapalene and 2.5% benzoyl peroxide in the country this year. Earlier this...
BC Week In Review | Sep 7, 2015
Company News

Galderma sales and marketing update

Galderma launched Epiduo Forte adapalene/benzoyl peroxide in the U.S. to treat acne vulgaris. The wholesale acquisition cost (WAC) for 45 g of the product is $398.10. Epiduo Forte is a once-daily topical gel formulation of...
BC Week In Review | Aug 3, 2015
Clinical News

Epiduo Forte adapalene 0 regulatory update

FDA approved an NDA from Galderma for Epiduo Forte adapalene/benzoyl peroxide to treat acne vulgaris. The company said it plans to launch the once-daily topical gel formulation of adapalene 0.3%, a synthetic retinoid, and benzoyl...
BC Week In Review | Apr 6, 2015
Clinical News

Adapalene 0: Phase III data

A double-blind Phase III trial in 503 patients ages >=12 with moderate to severe acne showed that once-daily 0.3% A/BPO met the co-primary endpoints of improving the success rate (33.7% vs. 11%, p<0.001) and of...
BC Week In Review | Feb 25, 2013
Clinical News

Epiduo adapalene/benzoyl peroxide regulatory update

Galderma said FDA approved an sNDA for Epiduo adapalene/benzoyl peroxide gel to treat acne vulgaris in patients 9 years and older. The gel formulation of adapalene and benzoyl peroxide, which Galderma said is immediately available,...
BC Week In Review | Jun 7, 2010
Company News

Galderma sales and marketing update

Galderma launched its Epiduo adapalene/benzoyl peroxide in the U.K. to treat acne vulgaris when comedones, papules and pustules are present. The price for the gel formulation of adapalene and benzoyl peroxide is £17.91 ($25.96). Galderma...
BC Week In Review | Mar 1, 2010
Clinical News

Epiduo adapalene/benzoyl peroxide: Post-marketing study data

The double-blind, post-marketing ACCESS trial in 459 patients showed that topical once-daily Epiduo plus 100 mg once-daily oral doxycycline met the primary endpoint of reducing total lesion count at week 12 vs. gel vehicles plus...
BC Week In Review | Dec 15, 2008
Clinical News

Epiduo adapalene/benzoyl peroxide regulatory update

FDA approved an NDA from Galderma for Epiduo adapalene/benzoyl peroxide (0.1%/2.5%) cream to treat acne vulgaris in patients 12 years and older. Galderma S.A. , Lausanne, Switzerland   Product: Epiduo adapalene/benzoyl peroxide   Business: Dermatology  ...
Items per page:
1 - 8 of 8